TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06521255: A Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refract

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 244 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,890,264

Rescue Site Savings

+$7,165,888

Unlock Full NCT06521255 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06521255 Rescue Dossier →